
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TRX319
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing
Tr1X Gets FDA Clearance for TRX319 CAR-Tr1 Treg Cell Therapy, Secures $50M Financing
Details : The financing for TRX319, a cell & gene therapy targeting CD19, will advance clinical development efforts.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 14, 2025
Lead Product(s) : TRX319
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : California Institute for Regenerative Medicine
Deal Size : $8.0 million
Deal Type : Funding
Tr1x Awarded $8 Million Cirm Grant for TRX103 Phase 1/2a Clinical Trial
Details : The funding aims to advance the development of TRX103 an engineered Tr1 Treg cell therapy for use in the prevention of GvHD in blood cancer patients undergoing mismatched stem cell transplants.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 04, 2025
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : California Institute for Regenerative Medicine
Deal Size : $8.0 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Moderate to Severe Refractory Crohn's Disease
Details : TRX103 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tr1X Announces FDA Clearance of IND Application for TRX103 for Refractory Crohn’s Disease
Details : TRX103, a first-in-class Type 1 Treg cell therapy candidate, which is being evaluated for the treatment of patients with treatment-refractory crohn’s disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 07, 2024
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tr1X Doses First Patient in GvHD Trial with TRX103, a Type 1 Treg Cell Therapy
Details : TRX103, a first-in-class Type 1 Treg cell therapy, is specifically designed for patients with autoimmune and inflammatory disorders, including those undergoing HSCT.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 10, 2024
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : TRX103 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hematologic Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : The Column Group
Deal Size : $75.0 million
Deal Type : Series A Financing
Tr1X Raises $75M for Universal CAR-Treg Therapies Development
Details : The net proceeds will be used to bring universal allogeneic regulatory T (Treg), including TRX103 and CAR-Treg cell therapies, TRX301, for autoimmune and inflammatory diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 17, 2024
Lead Product(s) : TRX103
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : The Column Group
Deal Size : $75.0 million
Deal Type : Series A Financing
